

RESULTS OF GENERAL MEETING

Botanix Pharmaceuticals Ltd (ASX:BOT) ("Botanix" or the "Company") wishes to advise pursuant to Listing Rule 3.13.2 that all resolutions presented at the General Meeting of Shareholders held today were carried by a poll.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises details of the resolutions and the votes received in respect of each resolution are set out in the attached summary.

Release authorised by the Board of Directors.

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which is progressing its lead product Sofdra for the treatment of primary axillary hyperhidrosis through FDA approval. FDA accepted the resubmission of the NDA for Sofdra in January 2024 as a complete response and confirmed a target approval timing for late June 2024. Sofdra is positioned to be a leading first line and second line therapy and potentially represents a safe and effective new option for patients.

The Company also has a pipeline of other products in late-stage clinical development for range of other dermatology conditions. To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries Corporate Communications Botanix Pharmaceuticals P: +61 8 6555 2945 investors@botanixpharma.com Investor enquiries Hannah Howlett WE Communications P: +61 450 648 064 hhowlett@we-worldwide.com Media enquiries Haley Chartres H^CK P: +61 423 139 163 haley@hck.digital

Disclosure of Proxy Votes

Botanix Pharmaceuticals Limited

General Meeting Friday, 01 March 2024



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

				Proxy Votes				Poll Results (if applicable)		
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Ratification of issue of Placement Shares to sophisticated and professional investors	Ρ	170,022,190	165,322,111 97.24%	1,523,493 0.90%	1,326,286	3,176,586 1.87%	171,997,265 99.12%	1,523,493 0.88%	4,326,286	Passed
2 Ratification of issue of Fee Options to Euroz Hartleys Limited (or its nominee(s))	Ρ	390,796,452	385,147,173 98.55%	2,445,493 0.63%	467,033	3,203,786 0.82%	391,849,527 99.38%	2,445,493 0.62%	3,467,033	Passed

